Searched for
AZD7442
AZ to seek India nod for antibody cocktailEvusheld is a combination of tixagevimab and cilgavimab. The drug received EUA in the US on Thursday for pre-exposure prophylaxis or preven...- AstraZeneca in touch with Indian authorities for approval to COVID drugThe company also said studies are underway to provide information on the impact of the new Omicron variant on Evusheld, which is being deve...
- Testing a new jab on fresh strain, says AstraZenecaThe company, along with Oxford University, has developed a vaccine platform to enable it to respond quickly to new variants that may emerge.
- COVID: New antibody treatment could offer up to 18 months' protection against severe diseaseThe treatment contains antibodies, which are usually produced naturally in response to a COVID infection or vaccination. They work by recog...
- Antibody injection treatment shows 'statistically significant' reduction in severe Covid-19, study saysAZD7442 is dubbed as the first long acting antibody (LAAB) with Phase III data to demonstrate benefit.
- AstraZeneca antibody drug important as preventative COVID-19 therapy: ExecutiveThe experimental monoclonal antibodies therapy, called AZD7442, reduced the risk of severe COVID-19 or death by half in non-hospitalised pa...
- AstraZeneca drug cocktail succeeds in late-stage study to treat COVID-19"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for m...
- AstraZeneca files for US approval of drug to prevent COVID-19The treatment, an antibody therapy called AZD7442, had reduced the risk of people developing any COVID-19 symptoms by 77% in a late-stage t...
- AstraZeneca working on vaccine to prevent and cure Covid: MD Gagandeep SinghAnglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...
- AstraZeneca hits snag in Covid drug developmentThe drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said ...
- AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patientsThe company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...
- AstraZeneca, U.S. agree 500,000 more supplies of COVID-19 antibody cocktailThe antibody therapy, which has yet to be approved by U.S. regulators, is designed to treat the disease rather than prevent it like the vac...
- Biopharma giant AstraZeneca begins coronavirus dual-use antibody drug trial in UKThe drug known as AZD7442 has the potential to be given as a preventative option for people exposed to the coronavirus, and to treat and pr...
Load More
